Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Lai, Chung Chih ^a   Sheng, Wang Huei ^b   Wang, Jann Tay ^b   Cheng, Aristine ^c   Chuang, Yu Chung ^b   Chen, Yee Chun ^b   Chang, Shan Chwen ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Creatine phosphokinase; Daptomycin; High dose; Treatment outcomes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DAPTOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BACTERIAL ARTHRITIS; BONE INFECTION; BONE MARROW SUPPRESSION; CATHETER INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COHORT ANALYSIS; CREATINE KINASE BLOOD LEVEL; CYTOPENIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; GRAM POSITIVE SEPSIS; HOSPITAL PATIENT; HUMAN; INFECTIOUS ARTHRITIS; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LENGTH OF STAY; LOEFFLER PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYOPATHY; OBSERVATIONAL STUDY; OSTEOMYELITIS; OUTCOME ASSESSMENT; PITT BACTEREMIA SCORE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCORING SYSTEM; SEPSIS; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; TAIWAN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INPATIENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SEPSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873176925     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-66     Document Type: Article

References (32)

1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38(12):1673-1681. 10.1086/420818, 15227611.
2. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355(7):653-665. 10.1056/NEJMoa053783, 16914701.
3. Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000, 46(4):523-526. 10.1093/jac/46.4.523, 11020247.
4. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302(21):2323-2329. 10.1001/jama.2009.1754, 19952319.
5. Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 2008, 46(3):1132-1136. 10.1128/JCM.01844-07, 2268353, 18199793.
6. Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A, Parent L, Ednie L, Koeth L, Bogdanovich T, et al. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother 2007, 51(9):3445-3448. 10.1128/AAC.00559-07, 2043240, 17620372.
7. Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008, 27(6):433-437. 10.1007/s10096-007-0455-5, 18214559.
8. Chambers HF, Basuino L, Diep BA, Steenbergen J, Zhang S, Tattevin P, Alder J. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob Agents Chemother 2009, 53(4):1463-1467. 10.1128/AAC.01307-08, 2663086, 19171803.
9. Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008, 52(9):3061-3067. 10.1128/AAC.00102-08, 2533470, 18591272.
10. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007, 60(2):334-340. 10.1093/jac/dkm170, 17540670.
11. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006, 50(10):3245-3249. 10.1128/AAC.00247-06, 1610083, 17005801.
12. Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E. Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents 2011, 38(3):192-196. 10.1016/j.ijantimicag.2011.03.006, 21549573.
13. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, de Florentiis D, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 2010, 36(5):459-461. 10.1016/j.ijantimicag.2010.07.011, 20846832.
14. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, Wehbeh W, Urban CM, Segal-Maurer S. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009, 49(2):177-180. 10.1086/600039, 19500039.
15. Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, Martone WJ. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 2008, 62(9):1455-1464. 10.1111/j.1742-1241.2008.01854.x, 18662172.
16. Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011, 31(6):527-536. 10.1592/phco.31.6.527, 21923436.
17. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother 2009, 43(7):1211-1219. 10.1345/aph.1M085, 19584384.
18. Lai CC, Sheng WH, Wang JT, Liao CH, Ho MW, Chen CJ, Chen DL, Chou MU, Lee CM, Lin YC, et al. Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections. J Microbiol Immunol Infect 2012, 45(1):52-57. 10.1016/j.jmii.2011.09.018, 22153759.
19. Liang SH, Sheng WH, Huang YT, Wu FL, Chang SC. Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chemotherapy 2009, 55(2):91-96. 10.1159/000192392, 19145078.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383. 10.1016/0021-9681(87)90171-8, 3558716.
21. Feldman C, Alanee S, Yu VL, Richards GA, Ortqvist A, Rello J, Chiou CC, Chedid MB, Wagener MM, Klugman KP. Severity of illness scoring systems in patients with bacteraemic pneumococcal pneumonia: implications for the intensive care unit care. Clin Microbiol Infect 2009, 15(9):850-857. 10.1111/j.1469-0691.2009.02901.x, 19702589.
22. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 18th informational supplement. M100-S18 2008, Clinical and Laboratory Standards Institute W, PA, Clinical and Laboratory Standards Institute.
23. Wang JT, Liao CH, Fang CT, Chie WC, Lai MS, Lauderdale TL, Lee WS, Huang JH, Chang SC. Prevalence of and risk factors for colonization by methicillin-resistant Staphylococcus aureus among adults in community settings in Taiwan. J Clin Microbiol 2009, 47(9):2957-2963. 10.1128/JCM.00853-09, 2738089, 19625471.
24. Boucher HW, Sakoulas G. Antimicrobial resistance: perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007, 45(5):601-608. 10.1086/520655, 17682996.
25. Chuang YC, Chang SC, Wang WK. High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy. PLoS One 2010, 5(11):e14133. 10.1371/journal.pone.0014133, 2994729, 21152436.
26. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010, 50(12):1568-1574. 10.1086/652767, 20462352.
27. Miller BA, Gray A, Leblanc TW, Sexton DJ, Martin AR, Slama TG. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis 2010, 50(11):e63-e68. 10.1086/652656, 20420515.
28. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 2007, 60(1):7-19. 10.1093/jac/dkm137, 17550889.
29. Lichterfeld M, Ferraro MJ, Davis BT. High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides. Int J Antimicrob Agents 2010, 35(1):96.
30. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006, 42(Suppl 1):S35-S39.
31. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012, 54(1):51-58. 10.1093/cid/cir764, 22109947.
32. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007, 51(8):2741-2747. 10.1128/AAC.00059-07, 1932544, 17548489.